AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06262204 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hallux Valgus Treatment with metal screw
Description: This is a prospective, randomised study in which hallux valgus is corrected by means of a chevron/kin surgery technique using metal screws or human allogenic cortical bone screws (Shark Screw®, Surgebright, Lichtenberg, Austria). X-rays are taken before the operation at 6 weeks, three, six and twelve months after the operation. The X-ray images provide information on whether bony degeneration has taken place. In addition, the American Orthopaedic Foot \& Ankle Society (AOFAS) hallux score, FFI score, hallux valgus angle (HVA) and intermetatarsal angle (IMA) are determined. These data are collected preoperatively and 4 weeks (HVA and IMA), six and twelve months postoperatively in order to rule out a change in the HVA and IMA and to document the changes in the AOFAS/FFI.
Study NCT05286268 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ischemia Modified Albumin
Description: Blood sampling at admission for measurement of IMA and suPAR levels and at day 10 from symptom onset (peak of symptoms) for IMA level. Samples will be collected in blood collection tubes containing K2EDTA as anticoagulant and serum separation gel tubes for SuPAR and IMA assays respectively. The samples will be centrifuged (at 3000 x g for 10 minutes) within the first 3 hours of sampling. Then, both plasma and serum samples will be placed in Eppendorf tubes and stored at -80oC. IMA levels will be determined according to the principles of the ACB assay, using the commercially available Ischemia Modified Albumin Assay Kit method (Abbexa LTD, Cambridge, UK), on the Architect c8000 automatic analytical system (Abbott, USA). SuPAR levels will be determined by the suPARnostic TurbiLatex quantitative turbidimetric immunoassay (ViroGates A/S, Denmark), also on the Architect c8000 automatic analytical system.
Study NCT06248801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin and Metformin-Test product
Description: Vildagliptin and Metformin tablets 50/1000 mg manufactured by Mylan Laboratories Limited, India
Study NCT06248801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin and Metformin-Reference product
Description: Vildagliptin and Metformin tablets 50/1000 mg manufactured by NOVARTIS PHARMA PRODUKTIONS GmbH, Germany.
Study NCT06373627 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: A hypnosis session takes place in 3 stages:~* An induction stage, where we move from an ordinary state of consciousness to a modified state of consciousness through dissociation.~* A work phase to deepen the hypnotic trance. This phase is fueled by the construction of suggestions and metaphors, analogous to those of the patient in pain.~* Finally, a return to the ordinary state of consciousness through re-association with the patient.
Study NCT06373627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional medications used for sedation-analgesia
Description: MEOPA + intravenous ketamine (0.5 mg/kg) + intraveinous midazolam (50µg/kg)
Study NCT06373627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medications used in addition to hypnosis
Description: MEOPA + intravenous ketamine (0.3 mg/kg)
Study NCT06385639 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic
Description: This clinical trial will last for 10 days, and each subject will have 4 follow-up visits (Day -1, Day 0, Day 10, Day 20).
Study NCT04840433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MACE
Description: Using magnetically assisted capsule endoscopy to examine oesophagus and stomach
Study NCT05160662 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: New guidlines
Description: New guidelines for this group are being developed using NICE guidelines (evidence-based recommendations for health and care in England) as a model and will be tested in clinical practice
Study NCT05437653 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Drink A
Description: 300 mL of a 22% high fat emulsion (Rapeseed oil, water, emulsifier)
Study NCT05036356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Headspace App
Description: A mobile-application (app) focusing on teaching and sustaining mental well-being.
Study NCT05437653 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Drink B
Description: 300 mL of isocaloric, iso-volumetric and iso-viscous carbohydrate drink (maltodextrin)
Study NCT06673511 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph node visualization
Description: Resect the developing lymph nodes and the systematic lymph nodes. Conduct postoperative follow-up and pay attention to the relevant indicators of the patient after surgery.
Study NCT06673511 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No visualization of lymph nodes
Description: Resect the systematic lymph nodes. Conduct postoperative follow-up and pay attention to the relevant indicators of the patient after surgery.
Study NCT05361733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XFB-19
Description: XFB-19 is a first-in-class synthetic tetra-peptide (Acetyl-Lys-D-Ala-D-Val-Asp-NH2) that inhibits the activation of the human CCAAT-enhancer binding protein beta (C/EBPβ) thus mediating the activation of lung myofibroblasts. Activation of myofibroblasts is responsible for the development of lung fibrosis in idiopathic pulmonary fibrosis (IPF).
Study NCT05361733 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No active ingredient drug use to blind participants and investigators
Study NCT05537493 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: It will be followed by exercising on whatsapp
Study NCT05537493 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face to face
Description: It will be followed by face to face
Study NCT05476913 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: geko™ device
Description: Neuromuscular electrical stimulation of the peroneal nerve
Study NCT05107388 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre Pro
Description: Measurements of interstitial glucose variations with FreeStyle Libre Pro
Study NCT04857892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254
Description: GSK3640254 will be administered via oral route.
Study NCT04857892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG
Description: DTG will be administered via oral route.
Study NCT04857892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254/DTG
Description: GSK3640254/DTG will be administered via oral route.
Study NCT06385639 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: This clinical trial will last for 10 days, and each subject will have 4 follow-up visits (Day -1, Day 0, Day 10, Day 20).
Study NCT06445062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-6236
Description: Oral tablet
Study NCT05241665 — intervention group
Intervention type: DEVICE
Intervention: SpectraWAVE Imaging System
Description: Coronary imaging
Study NCT06445062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 regimen
Description: IV infusion
Study NCT06391567 — intervention group
Intervention type: OTHER
Intervention: There was no intervention in this study.
Description: There was no intervention in this study.
Study NCT05955105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ILB-2109
Description: ILB-2109 tablets will be administered by mouth every day in 21-day cycles
Study NCT05955105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab injection will be administered via IV every 21 days.
Study NCT05135117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NeuroRescue Cooling Collar
Description: Between bouts of exercise subjects will be provided cooling on the neck with the NeuroRescue Collar. The custom sized cooling collar has ice water (which is kept around 2 degrees celsius) that is circulated through a neoprene sleeve that is attached to their neck for the cooling period.
Study NCT05135117 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ice Towel
Description: Between bouts of exercise subjects will be provided cooling on the neck with a towel. The towel will be kept in ice water (which is kept around 2 degrees celsius) and placed around the neck of the individual during the cooling intervention period.
Study NCT05664555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescein Sodium
Description: Patients will receive Fluorescein Sodium 3mL (300mg) or 1mL (100mg) intravenously prior to fluorescein angiography.
Study NCT05664555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorescein Sodium
Description: Patients will receive Fluorescein Sodium 3mL (300mg) or 1mL (100mg) intravenously prior to fluorescein angiography.
Study NCT06445062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: IV infusion
Study NCT06445062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX regimen
Description: IV infusion
Study NCT06445062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: IV infusion
Study NCT06383819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Longidaza®
Description: dose 3000 IU intramuscularly once every 5 days, 15 injections
Study NCT06383819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intramuscularly once every 5 days, 15 injections
Study NCT05401903 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic Maintenance Care
Description: Subjects will receive high-velocity, low amplitude (HVLA) chiropractic manipulations to areas of defined restriction in the upper cervical spine, thoracic spine, lumbar spine, and pelvis. The clinician will use motion palpation to determine spinal segments with joint restrictions. Subjects will schedule weekly chiropractic visits.~The clinician will not use passive care modalities. The exclusions of passive modalities include heat and cold therapies, electric stimulation, massage, acupuncture, and cupping therapies. Subjects will be encouraged to maintain normal exercise activity levels throughout the study. The clinician will provide instructions on homecare exercises as needed to promote range of motion of spinal segments between chiropractic visits. A single clinician will deliver the HVLA chiropractic manipulations to ensure consistency of chiropractic care throughout the study.
Study NCT05666908 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNO
Description: After the patient's mask-assisted ventilation makes the end-expiratory oxygen concentration (EtO2) > 90%, wear the HFNO device according to the pre-adjusted mode (temperature 34°C, oxygen concentration 100%, flow rate 50 litres per minute). The nasal cannula will remain in place until intubation is complete (including DLT intubation, direct FOB guidance, and DLT alignment with FOB). After securing the HFNO device, the glottis was exposed using a laryngoscope, and the DLT main tracheal cuff was passed through the glottis and paused under direct vision. Insert the DLT into the bronchial tube lumen of the DLT using the FOB, and then advance the DLT into the corresponding main bronchus under the guidance of the FOB. After confirming the appropriate depth of the catheter using the FOB, insert the DLT into the anesthesia machine to complete the intubation process. After the DLT was connected to the anesthesia machine and mechanical ventilation was started, the HFNO device was removed.
Study NCT05380960 — intervention group
Intervention type: DEVICE
Intervention: cbc coaglation profile
Description: The Demographic, clinical, and laboratory data for the enrolled subjects will be collected. To assess the coagulability state in the participants, we will measure the levels of certain markers in the blood that are thought to be associated with an increased coagulability. A comparison will be made between the different included groups regarding the level of these markers. These markers included complete blood count (CBC) indices (hematocrit, red cell distribution width, platelets count, mean platelet volume and platelet distribution width), C - reactive protein, d dimer, and blood coagulation tests (prothrombin time, international normalized ratio and partial thromboplastin time).
Study NCT06430645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Sufentanil(0.1ug/kg) and flurbiprofen axetil(50mg) are administered before induction. Propofol (10 mg/ml) is infused via target-controlled infusions (TCIs). Esketamine hydrochloride (0.3mg/kg total body weight) single intravenous injection after stable plasma concentration of propofol deep sedation.
Study NCT06430645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Sufentanil(0.1ug/kg) and flurbiprofen axetil(50mg) are administered before induction. Propofol (10 mg/ml) is infused via target-controlled infusions (TCIs). Esketamine hydrochloride (0.6mg/kg total body weight) single intravenous injection after stable plasma concentration of propofol deep sedation.
Study NCT06430645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Sufentanil(0.1ug/kg) and flurbiprofen axetil(50mg) are administered before induction. Propofol (10 mg/ml) is infused via target-controlled infusions (TCIs). The same volume of 0.9% saline instead of esketamine will be given to the control group after stable plasma concentration of propofol deep sedation.
Study NCT06451276 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasoalveolar molding in unilateral cleft lip and palate
Description: compare the effectiveness of adhesive nasoalveolar molding (GS-NAM) and conventional nasoalveolar molding on the alveolar ridge, nasal, and labial growth in children with unilateral cleft lip and palate
Study NCT06451276 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasoalveolar molding in unilateral cleft lip and palate
Description: compare the effectiveness of adhesive nasoalveolar molding (GS-NAM) and conventional nasoalveolar molding on the alveolar ridge, nasal, and labial growth in children with unilateral cleft lip and palate
Study NCT06343454 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Digital Interocclusal Record In Different Head Positions
Description: Recording the position of the upper and lower teeth in the bite position in different head positions with an intraoral scanner
Study NCT06445062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: IV infusion
Study NCT06445062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: IV infusion
Study NCT06445062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-9805
Description: Oral Tablet
Study NCT04966273 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microcatheter
Description: Only to be used if Biosensor Microcatheter does not perform accordingly
Study NCT04647721 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiesse injectable implant (dermal filler)
Description: Subdermal injection.
Study NCT04647721 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane injectable implant (dermal filler)
Description: Subdermal injection.
Study NCT05865730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Live Bacterial Product - Akkermansia muciniphila
Description: Oral administration of Oncobax-AK to patients deficient in Akkermansia by stool metagenomic analysis.
Study NCT06436820 — intervention group
Intervention type: PROCEDURE
Intervention: Lumbar puncture
Description: Lumbar puncture procedure performed within a clinical setting
Study NCT06316648 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whey intake group
Description: It was prepared at the bedside by the first investigator for the patients in the oral whey intervention group by mixing 54 grams of 70% demineralized whey powder taken from the herbalist into 600 ml of drinking water six hours before the surgery, and the patients were given 400 ml six hours before the surgery and 200 ml two hours before the surgery. They were given ml and allowed to drink.
Study NCT06316648 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: The patients were left fasting after 00:00.
Study NCT04694716 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be applied.
Study NCT04859543 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FoundationOneHeme
Description: Tumor tissue obtained during standard surgery will be subsequently examined histopathologically and the content of cancer cells will be determined. Broad molecular profiling of the tumor; with potential results finding such molecular changes, for which the specific targeted anti-tumor treatment will be performed.
Study NCT05988632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Human Insulin then Placebo
Description: Insulin: 80 IU (administered intranasally) THEN Placebo: 0.9% saline solution (administered intranasally)
Study NCT05988632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo then Regular Human Insulin
Description: Placebo: 0.9% saline solution (administered intranasally) THEN Insulin: 80 IU (administered intranasally)
Study NCT04571151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEXETTE 0.05% Topical Foam
Description: Halobetasol Propionate Topical Foam (Lexette Foam) would be applied over the affected area twice daily for 2 weeks.
Study NCT04571151 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEXETTE 0.05% Topical Foam
Description: Halobetasol Propionate Topical Foam (Lexette Foam) would be applied over the affected area twice daily for 2 weeks.
Study NCT04571151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorilux 0.005 % Topical Foam
Description: Calcipotriol Foam (Sorilux Foam) would be applied over the affected area twice daily for 2 weeks 5 minutes after the Lexette application. SORILUX Foam contains calcipotriene 50 mcg/g.
Study NCT04571151 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: Vehicle Foam would be applied over the affected area twice daily for 6 weeks.
Study NCT04746677 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular aortic repair with a physician-modified endovascular graft (PMEG)
Description: Endovascular aortic repair with a physician-modified endovascular graft (PMEG)
Study NCT05750862 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Marking of the intended axis of IOL-Implantation manually with an ink and marking device on the surface of the eye
Description: The marking of the intended implantation axis of the interocular lens will be marked in all patients with topography guided in the corneal stroma with laser and in addition manually with a caliper and ink on the corneal surface
Study NCT05191017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUV-422
Description: NUV-422 is an investigational drug for oral dosing.
Study NCT05191017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide
Study NCT04819048 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy+acupuncture
Description: The experimental group will be firstly irradiated by the GaAlAs infrared laser (CDHC,Denlase 980/7 Diode Laser Therapy System,China), with an output of 500 mW, emitting radiation wavelength of 980 nm, spot size 0.2cm2 ,15J/point, in a continuous mode .The therapeutic LLLT application is achieved through direct contact of the probe on the skin.~The needles using are disposable, sterile, individually packed, and made of stainless steel (Hua Tuo; Suzhou Medical Supplies Factory Co, Ltd,Suzhou, China), in sizes 0.25 mm ×40 mm.Asepsis of the skin will be performed with cotton wool and 75% alcohol.
Study NCT04819048 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-Level Laser Therapy
Description: The experimental group will be firstly irradiated by the GaAlAs infrared laser (CDHC,Denlase 980/7 Diode Laser Therapy System,China), with an output of 500 mW, emitting radiation wavelength of 980 nm, spot size 0.2cm2 ,15J/point, in a continuous mode .The therapeutic LLLT application is achieved through direct contact of the probe on the skin.
Study NCT05084716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced PrEP provision
Description: At the intervention site during healthcare facility outreach events, all community members will be offered the opportunity to attend intervention workshops where they can learn basic facts about PrEP and be taught skills about how to advocate for PrEP in their community. Check-in reminder calls will be conducted systematically with PrEP users. Healthcare facility staff will encourage PrEP initiators to select an adherence supporter.
Study NCT06330181 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VR Game 1
Description: Individuals playing VR game 1 will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart